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"COLCEMID " (desacetylmethylcolchicine) has been reported as a useful drug
in the treatment of chronic myeloid leukaemia, without any serious side effects
(Moeschlin, Meyer and Lichtman, 1953; Leonard and Wilkinson, 1955). Our
experience has been limited to the treatment of four patients. The results in
this small series appear to confirm that " colcemid " will control the disease
successfully for a variable period of time in some, but not all, patient§, but we do
not consider that the toxic effects of this drug can be dismissed as unimportant.
CASE HISTORIES
Case 1
A woman aged 58 was found to have chronic myeloid leukaemia in June 1953.
Examination of the blood at that time showed a total white cell count of 500,000
per cu. mm., 87 per cent neutrophils and myeloid precursors. The disease
responded to splenic irradiation. Further courses were given with gradually
diminishing remissions until July 1955. She was then admitted to hospital as
there had been a recent deterioration in her condition. The liver and spleen were
enlarged down to the level of the umbilicus and in addition she had developed a
generalised adenopathy. Blood examination showed a total white cell count
of 57,000 per cu. mm., 67 per cent neutrophils, 12 per cent myeloid precursors;
haemoglobin 40 per cent. She failed to respond to blood transfusions, cortisone,
6-mercaptopurine and " colcemid " and died two months after admission.-
Case 2
A man aged 60 was found to have polycythaemia in 1947. He received
treatment with deep X-rays to the skeleton and later with P.32. The total white
cell count was always high and by May 1955 it had risen to 62,000 per cu. mm.,
92 per cent neutrophils, 5 per cent myeloid precursors. He was also having a
considerable amount of pain from the very marked splenic enlargement. Bone
marrow aspiration showed a generalised hyperplasia of all elements. He was
given a course of deep X-rays to the spleen, which became impalpable, the white
count falling to 40,000 per cu. mm. Six months later the spleen tip could be
felt level with the umbilicus and he again complained of pain. The white cell
count was 78,000 per cu. mm. but the haemoglobin remained at 108 per cent.
The spleen was treated by irradiation three times in the next 18 months with a
decreasing response on each oecasion, The highest total white cell count recordedDESACETYLMETHYLCOLCHICINE IN MYELOID LEUKAEMIA
during this period was 126,000 per cu. mm. In November 1955 the patient
strained his shoulder while gardening and was admitted two days later as an
emergency with an extensive bruise over the right side of the chest. He was
also complaining of severe pain from the enlarged spleen which was now palpable
in the left iliac fossa. Investigation of the blood showed a haemoglobin of 60
per cent; total white blood cells 146,000 per cu. mm., 83 per- cent neutrophils,
10 per cent neutrophil precursors; platelet count 525,000 per cu. mm. He was
treated with " colcemid " with an immediate fall in the white cell count and a
rise in the haemoglobin, with some diminution in the size of the spleen. The
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FIG. 1.-Case 2: Effect of " colcemid " on total white cells. Rapid response on reducing
daily dose from 5 mg. to 3 mg.
5 mg. to 3 mg. (Fig. 1). The patient died of hypostatic pneumonia before any
further observations could be made.
Case 3
A 30-year-old woman was investigated elsewhere in February 1952 for
abdominal discomfort of six months' duration. She was found to have chronic
myeloid leukaemia with a total white blood cell count of 223,000 per cu. mm. and
a haemoglobin of 68 per cent. A satisfactory remission followed a course ofdeep
X-ray therapy to the spleen. Thirteen months later the white cell count had
risen to 131,000 per cu. mm, and it again fell rapidly with irradiation, Between
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J-anuary 1954 and March 1955, three courses of deep X-ray therapy were
necessary to control her symptoms and blood count. Each remission was of
progressively shorter duration, and it was decided to try the effect of myleran.
For 30 days 4 mg. daily were given with some effect on the blood count. The
patient was then found to be pregnant. It was thought that this might lead to a
deterioration ofher leukaemia and, as she already had two children, a hysterotomy
was combined with sterilisation. Three months later the total white cell count
had risen to 140,000 per cu. mm. and she was again having pain in the left sub-
costal region. Deep X-ray therapy to the spleen produced a rapid response but
the remission was short, and three months later the total white cell count had
FuA. 2.-Case 3: Resistance to "coleemid " in case responding to X-ray therapy and myleran.
increased to 170,000 per cu. mm. She felt very ill, had lost weight and was again
complaining of pain in the splenic region. Treatment with " colcemid " was
started with 2 mg. twice daily by mouth. The dose was gradually increased,
without any improvement, until a daily total of 10 mg. was reached. At this
level, the white cell count showed a slight response, but unfortunately this was
not maintaned. The daily dose was then gradually raised to 13 mg. without any
benefit. The total white cell count showed no real decrease, the haemoglobin
level did not rise appreciably and the spleen remained unaltered in size. The
patient continued to feel lethargic and generally unwell, and she became extremely
depressed, worrying a great deal over her failure to respond to treatment. It
was decided to give myleran a further trial, using a larger initial dose than 4 mg.
daily, as this had not proved very effective previously. A satisfactory remission
occurred and the total white cell count fell rapidly with a simultaneous rise in
the haemoglobin (Fig. 2).
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Case 4
A man aged 37 was admitted to hospital as an emergency in September 1955
with severe pain in the left upper abdomen and shoulder, which had been present
for three days. He was found to have a firm tender spleen, enlarged to just above
the umbiJicus. Examination of the blood showed a haemoglobin of 67 per cent
and a total white cell count of 148,000 per cu. mm. with a differential count
typical of chronic myeloid leukaemia, and the diagnosis was confirmed by bone
marrow aspiration. Deep X-ray therapy was given to the spleen, which became
impalpable, and the blood count responded satisfactorily. Five months later
the total white blood count had increased to 142,000 per cu. mm. and the
haemoglobin had fallen. At his next hospital attendance four weeks later he
complained once more of left-sided pain and extreme lethargy. It was decided
to try the effect of " colcemid ". A satisfactory initial response occurred, and
this was maintained on 6 mg. daily in divided doses. The spleen, which had
again enlarged to the level of the umbilicus, became painless, but there was no
decrease in size during the treatment. His appetite and weight improved and he
felt increasingly fit. Unfortunately, the platelet count fell slowly to 90,000 per
cu. mm., and the drug was stopped after a symptom-free remission offive months.
Two weeks later, the total white count had risen to 110,000 and the haemo-
globin was falling. The patient felt unwell and the original pain returned.
Further irradiation was given to the spleen with an immediate fall in the total
white cell count and a simultaneous subjective improvement. The spleen shrank
a little but the response was disappointing. This remission lasted only two
months. Theplatelet count had bynowrisento over 200,000 per cu. mm. and itwas
decided to try " colcemid " once more. The total white cell count fell rapidly
but there was no increase in the haemoglobin level. The drug was stopped for
12 days over Christmas and was recommenced on December 29. Two days later
the patient felt extremely ill and his hair suddenly began to fall out. Three
days after this he attended for follow-up examination. " Colcemid "was stopped
and he was admitted to hospital. There was by this time a severe generalised
loss of scalp hair and quantities of hair could easily be removed by gentle
combing. He had also noticed thinning of the hair over the rest of the body.
His general condition was poor, with pitting oedema of both ankles. The spleen
was palpable below the level of the umbilicus and the liver was enlarged to just
above this level.
The following relevant investigations were carried out. Blood count: Hb
30 per cent. W.B.C. 107,000 per cu. mm. Neutrophils 17 per cent. Lympho-
cytes 6 per cent. Monocytes 2 per cent. Eosinophils 1 per cent. Basophils
2 per cent. Metamyelocytes 2 per cent. Myelocytes 43 per cent. Premyelo-
cytes 2 per cent. Myeloblasts 25 per cent. 38 nucleated red cells/100 white cells.
Platelets 77,000 per cu. mm. Bone marrow aspiration: differential count
identical with peripheral blood. Bone marrow biopsy: Acellular marrow with
some increase of fibrous tissue. Serum bilirubin: 1 1 mg. per cent.
Reticulocytes: 1 per cent. Coombes test: negative.
A diagnosis of generalised marrow aplasia was made, and further treatment
with any cytotoxic drug was thought to be contra-indicated. Repeated blood
transfusions, prednisone and cortisone were given to try to postpone the inevitable
outcome. Small doses ofX-rays were given to the spleen in an attempt to reduce
its size and relieve the patient's discomfort but none of these measures appeare(d
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to affect his rapid downhill progress. Terminally the total white cell count rose
to over 400,000 per cu. mm., 67 per cent ofwhich were myeloid precursors, and he
finally died six weeks after admission to hospital (Fig. 3).
Four days before his death he complained of variable left-sided lower
abdominal pain, radiating down the left leg above the knee, and an area of
anaesthesia to pin prick and light touch was found over the anterior surface ofthe
affected thigh. The spleen had by then enlarged until it completely filled the
FrG. - 4 * b d ", follwed .
left iliac fossa, and these findings were thought to be due to nerve pressure or
actual invasion by the leukaemic process. The autopsy proved these assumptions
to be incorrect. During the first two weeks of his stay in hospital, depilation
continued at a gradually diminishing rate and over the last week of his life it was
thought that there had been some slight regrowth of hair.
Post-mortem examination showed that the spleen was grossly enlarged,
weighing 7 lb., and its surface was mottled by old and recent infarcts. The liver
weighed 8 lb. and was pale, the macroscopical appearance suggesting myeloid
leukaemia. The, bone marrow in all the bones examined was pale. On the left
lateral and postero-lateral wall of the abdominal cavity, there was a large smooth
swelling, pushing the spleen down and the kidney upwards. When the swelling
was incised about 21 pints of semi-solid blood clot was evacuated.
On microscopical examination, the typical changes ofmyeloid leukaemia were
found in the liver, spleen and kidneys. The marrow from all areas was highly
cellular. Megakaryocytes and red blood cells were completely absent, and the
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cells consisted almost entirely of primitive white cells. The testicles showed a
marked maturation defect and skin from both the scalp and the scrotum showed
a number of normal hair follicles.
DISCUSSION
Case 1 did not respond to " colcemid " or to any form of treatment. This is
not surprising, in view of the advanced stage of the disease.
Case 2 showed a marked fall in the white cell count, associated with a rapidly
rising haemoglobin, and some decrease in the size of the spleen. Reduction of
the dose of " colcemid " led to an immediate rise in the white cell count. The
unexpected death ofthe patient from bronchopneumonia unfortunately prevented
any further observations. This complication cannot be attributed to the drug.
Case 3 proved resistant to " colcemid " in doses of up to a maximum of 13
mg. daily. Leonard and Wilkinson (1955) refer to two out of a total of eight
patients with chronic myeloid leukaemia who were resistant to " colcemid " up
to a maximum dose of 10 mg. daily. Both their cases were also resistant to
myleran and 6-mercaptopurine. No mention is made if they responded to radio-
therapy, either before or after " colcemid" therapy. Our case was resistant to
" colcemid " but responded to splenic irradiation and to myleran. Resistance
to " colcemid " does not therefore mean that other methods of treatment will be
unsuccessful.
Case 4 developed loss of scalp hair, which was referred to by Leonard and
Wilkinson (1955) as acomplication in one oftheircases. Theirpatient also noticed
some dysphagia and scrotal tenderness, and the hair loss occurred at the height
ofthe depression of the white cells. No mention is made ofregrowth ofthe hair,
and treatment with " colcemid " was abandoned. Our patient developed severe
generalised alopecia of the whole scalp and loss of hair in the axillae and on the
eyebrows and scrotum. It occurred during the second course of " colcemid " and
we are unable to relate this directly to the degree of depression of the white cell
count. Although the count at this time was low, the fall was not as marked as it
had been onprevious occasions during the first course oftreatment. No dysphagia
or scrotal irritation was noticed and there was no eosinophilia.
This complication has been noted previously during the treatment of human
cancer with large doses of colchicine (Seed, Slaughter and Limarzi, 1940). A
woman aged 55 with advanced carcinoma of the breast was given intramuscular
injections of the drug with some temporary improvement in the tumour. On
the 21st day ofthe treatment her scalp hair suddenly started to fall out in handfuls
and in four days she was totally bald. She continued to have injections of
colchicine for a further six weeks and, in spite of this, complete regrowth of the
scalp hair occurred in five months. If the alopecia produced by " colcemid " is
similar, regrowth of the hair may be expected and this was suggested by the
findings in our case. It is possible that regrowth of the hair might occur during
the continued administration of " colcemid ", but it would require a certain
amount of courage to test out this hypothesis.
Before the death of the patient it was thought that marrow failure had
developed as a result of treatment, and for this reason no further chemotherapy
was given. Although no case of marrow aplasia following the use of " colcemid "
had been reported previously, this complication was attributed to the drug
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rather than to the inatural progress of the disease. The alternative diagnosis of
myelosclerosis was considered unlikely as the original bone marrow examination
had shown the typical findings of chronic myeloid leukaemia. Some authors
believe that myeloid leukaemia and myelosclerosis are one and the same disease
(Heller, Lewisohn and Palin, 1947). In fact very few untreated cases have beell
recorded where the original bone marrow examination showed frank myeloid
leukaemia to be followed at a later date by the development of myelosclerosis.
Post-mortem examination showed that failure of the marrow was due to
extensive invasion by primitive forms ofthe myeloid series. All marrow specimens
examined showed these changes, emphasising the danger ofrelying on the examina-
tion of one sample of bone marrow. In light of this knowledge, the response of
the leukaemia to the treatment was reviewed and it appeared that " colcemid "
was in fact controlling the disease. When the drug was finally stopped, the total
count rapidly rose and large numbers of primitive cells of the myeloid series
appeared in the peripheral circulation. An alternative explanation that might
be offered for the final exacerbation is that the " colcemid " stimulated the
leukaemia into an acute phase. Similar charges have been made against deep
X-ray therapy, and irradiation is still sometimes blamed when chronic leukaemia
enters a terminal acute phase or when the changes oflymphatic leukaemia become
mnanifest in the course of progress of a case of lymphosarcoma. There is very
little knowledge of the natural history of untreated leukaemia and without
control series of cases, such criticisms must be without foundation.
The chemotherapeutic control of chronic myeloid leukaemia has been achieved
for long periods of time without serious complications (Galton and Till, 1955).
When chemotherapeutic agents are used it is important that they should be as free
from unpleasant side effects, as effective and as easily administered as X-ray
therapy. From the small amount of evidence available, we do not consider that
" colcemid " is as free from distressing side effects or more effective than X-ray
therapy or myleran. We do not think it should be used in the treatmenit of
chronic myeloid leukaemia unless the patient has become refractory both to
irradiation and to myleran. Leonard and Wilkinson (1955) refer to the dangers
of myleran but it would appear that these have been almost entirely elimilnated by
the adoption of more suitable dosage schedules (Galton and Till, 19.55).
" Colcemid " seems to be contra-indicated particularly in the treatment ofwomen,
but it might be used with less anxiety if the patient is a man who is already bald.
The drug is effective in controlling some cases of chronic myeloid leukaemia amid
so far there is no evidence that serious marrow depression follows its use.
SUMMARY
Aul account is giveni of the treatmenit of mlyeloid leukaemiiia witlh (lesacetyl-
mlethylcolchicine. The drug appears to be an additional effective -weapon ill
the control of some patients with this disease.
There has been as yet no recorded case of dangerous bonie marrow depressioni
during " colcemid " administration, anid the only serious toxic effect encountered
has been depilation, which is probably reversible.
Depilation is a distressing complication and we do( not think " colceenid
should be used in the treatment of chronic myeloid leukaemia, unless the patient
no longer responds to splenic irradiation and to mnyleran.
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